METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS
Clinical trials for METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS explained in plain language.
Never miss a new study
Get alerted when new METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS trials appear
Sign up with your email to follow new studies for METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Could a simple stomach tuck reverse fatty liver disease?
Disease control Recruiting nowThis study tests whether a minimally invasive procedure called endoscopic sleeve gastroplasty (ESG), which reduces stomach size by about 70%, can help people with obesity and a serious liver condition called MASH. Participants will be randomly assigned to receive either ESG plus …
Matched conditions: METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS
Phase: NA • Sponsor: Pichamol Jirapinyo, MD, MPH • Aim: Disease control
Last updated May 26, 2026 10:02 UTC
-
New weekly shot could slow liver damage in NASH cirrhosis patients
Disease control Recruiting nowThis study tests a medicine called survodutide in 1590 adults with NASH or MASH cirrhosis, a serious liver condition. Participants receive either the drug or a placebo as a weekly injection for up to 4.5 years, along with diet and exercise advice. The goal is to see if survodutid…
Matched conditions: METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS
Phase: PHASE3 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated May 26, 2026 09:59 UTC
-
New drug trial targets fatty liver disease – could it reduce liver fat?
Disease control Recruiting nowThis study tests an experimental drug called ALN-CIDEB in adults with fatty liver disease (MASLD or MASH). The goal is to check safety and how well the drug reduces liver fat. About 132 participants will receive either the drug or a placebo. The study is currently recruiting.
Matched conditions: METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS
Phase: PHASE1, PHASE2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated May 26, 2026 09:59 UTC
-
New drug hopes to slow liver scarring in MASH patients
Disease control Recruiting nowThis study tests an experimental drug called efimosfermin alfa in 42 adults with liver scarring (cirrhosis) caused by MASH, a fatty liver disease. The main goal is to see if the drug is safe and how the body processes it. Participants will receive either the drug or a placebo, an…
Matched conditions: METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS
Phase: PHASE2 • Sponsor: Boston Pharmaceuticals • Aim: Disease control
Last updated May 26, 2026 09:50 UTC
-
New drug combo aims to melt liver fat in MASH patients
Disease control Recruiting nowThis study tests two experimental drugs, ECC4703 and ECC0509, alone or together, to see if they can reduce fat buildup in the liver of people with MASH (a serious fatty liver disease). About 160 adults with MASH will take the drugs or a placebo for 12 weeks. The main goal is to m…
Matched conditions: METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS
Phase: PHASE2 • Sponsor: Eccogene • Aim: Disease control
Last updated May 22, 2026 13:54 UTC
-
Tiny cell talk may hold key to fatty liver disease
Knowledge-focused Recruiting nowThis study looks at 20 adults having weight-loss surgery to understand how a breakdown in communication between parts of liver cells might lead to MASH, a serious liver condition. Researchers will take small liver samples during surgery and blood tests before and after to track t…
Matched conditions: METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS
Sponsor: Hospices Civils de Lyon • Aim: Knowledge-focused
Last updated May 26, 2026 09:48 UTC
-
Healthy volunteers test new liver drug with breakfast
Knowledge-focused Recruiting nowThis early-stage study tests a new drug called ECC4703 in 72 healthy adults. The goal is to see if taking the drug with food changes how the body absorbs it. Participants will receive a single dose of the drug in different forms, and researchers will measure drug levels in the bl…
Matched conditions: METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS
Phase: PHASE1 • Sponsor: Eccogene • Aim: Knowledge-focused
Last updated May 19, 2026 12:00 UTC